The approval is based on the pivotal TRIDENT-1 trial, in which AUGTYRO achieved a high response rate and durable responses, including robust...
Net product revenue of $87.1 million for the first quarter of 2024, representing 39% y-o-y growth; 43% y-o-y growth at constant exchange rate...
- Company to Host Conference Call and Webcast on May 9, 2024, at 8:00 a.m. ET (8:00 p.m. HKT) Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today...
The Executive Officers of Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), Samantha Du, Josh Smiley, Rafael Amado, Harald Reinhart, Yajing Chen, F. Ty...
Poster sessions to highlight Phase 1 trials of internal oncology candidates ZL-1310, a next-generation antibody-drug conjugate for small cell...
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of...
The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with Tumor Treating Fields and supportive...
ZL-1310 is an innovative ADC targeting DLL3, a promising therapeutic target in small cell lung cancer and other DLL3+ solid tumors Data will be...
- Findings will be shared in oral presentations at the 2024 Congress of the European Society of Gynaecological Oncology (ESGO) and the 2024...
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.